Tuberous sclerosis (also known as tuberous sclerosis complex [TSC]) is a multisystem
genetic disorder that affects almost every organ in the body. Mutations in the TSC1 or TSC2 …

Patients with tuberous sclerosis complex (TSC) are at very high risk for developing epilepsy,
and the majority experience seizure onset during the first year of life. Early targeted …

Background Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used
for various benign tumours associated with tuberous sclerosis complex. We assessed the …

Background Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has
demonstrated efficacy in treating subependymal giant cell astrocytomas (SEGAs) and other …

Background Tuberous sclerosis complex is a multiorgan disease resulting from a mutation of
one of two TSC genes. The two gene products form a functional complex that regulates the …

Glioma accounts for the majority of human brain tumors. With prevailing treatment regimens,
the patients have poor survival rates. In spite of current development in mainstream glioma …

This article describes the recent advances in epileptogenesis and novel therapeutic
approaches for the prevention of epilepsy, with a special emphasis on the pharmacological …

The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase
activity which controls cell viability being key in the PI3K/PTEN/Akt pathway. mTOR acts by …

Tuberous sclerosis complex (TSC) is a genetic disorder arising from mutations in the TSC1
or TSC2 genes. The resulting over-activation of the mammalian target of rapamycin (mTOR) …

Background Epilepsy occurs in up to 90% of all individuals with tuberous sclerosis complex
(TSC). In 67% disease onset is during childhood. In≥ 50% seizures are refractory to …